FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

Kocaeli University129 enrolled

Overview

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Study Type

OBSERVATIONAL

Enrollment

129

Conditions

Vaccine Reaction Oncology

Interventions

F-18 FDG PET/CT imagingDIAGNOSTIC_TEST

Oncological imaging

Pfizer/biontech mRNA vaccineBIOLOGICAL

COVID-19 vaccine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients referred for post-vaccination FDG PET/CT imaging Exclusion Criteria: * Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria

Locations (1)

Kocaeli University School of Medicine Dep. of Nuclear Medicine

Kocaeli, Turkey (Türkiye)

Outcomes

Primary Outcomes

to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine

Frequency of metabolic changes

Time frame: 5 month

to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine

FDG intensity of metabolic changes

Time frame: 5 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.